NASDAQ:ALXN - Alexion Pharmaceuticals Stock Price, Forecast & News

Alexion Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALXN."

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) issued its quarterly earnings results on Wednesday, October, 23rd. The biopharmaceutical company reported $2.79 EPS for the quarter, topping the consensus estimate of $2.47 by $0.32. The biopharmaceutical company earned $1.26 billion during the quarter, compared to analysts' expectations of $1.24 billion. Alexion Pharmaceuticals had a net margin of 31.05% and a return on equity of 21.21%. Alexion Pharmaceuticals's revenue was up 23.0% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.02 EPS. View Alexion Pharmaceuticals' Earnings History.

Alexion Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, January 30th 2020. View Earnings Estimates for Alexion Pharmaceuticals.

Alexion Pharmaceuticals will be holding an earnings conference call on Thursday, January 30th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Alexion Pharmaceuticals issued an update on its FY 2019 IntraDay earnings guidance on Monday, January, 13th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $4.95744 billion, compared to the consensus revenue estimate of $4.91 billion.

19 brokerages have issued twelve-month price targets for Alexion Pharmaceuticals' stock. Their forecasts range from $125.00 to $186.00. On average, they expect Alexion Pharmaceuticals' share price to reach $154.39 in the next year. This suggests a possible upside of 46.7% from the stock's current price. View Analyst Price Targets for Alexion Pharmaceuticals.

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alexion Pharmaceuticals in the last year. There are currently 4 hold ratings and 15 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Alexion Pharmaceuticals.

Press coverage about ALXN stock has trended somewhat negative on Monday, according to InfoTrie. InfoTrie rates the sentiment of press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Alexion Pharmaceuticals earned a coverage optimism score of -1.4 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Alexion Pharmaceuticals.

Some companies that are related to Alexion Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS), Exelixis (EXEL) and Repligen (RGEN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Alexion Pharmaceuticals investors own include Alibaba Group (BABA), Celgene (CELG), Micron Technology (MU), Gilead Sciences (GILD), NVIDIA (NVDA), Netflix (NFLX), AbbVie (ABBV), Visa (V), Broadcom (AVGO) and UnitedHealth Group (UNH).

Alexion Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Calamos Advisors LLC (0.31%), Candriam Luxembourg S.C.A. (0.26%), Strs Ohio (0.21%), New York State Teachers Retirement System (0.14%), State of Michigan Retirement System (0.12%) and Empire Life Investments Inc. (0.11%). Company insiders that own Alexion Pharmaceuticals stock include Aradhana Sarin, Bros Advisors Lp Baker, Christopher J Coughlin, Daniel Bazarko, Heidi L Wagner, Indrani Lall Franchini, John B Moriarty, John J Orloff, Julie O'neill, Ludwig Hantson and Paul J Clancy. View Institutional Ownership Trends for Alexion Pharmaceuticals.

ALXN stock was sold by a variety of institutional investors in the last quarter, including Strs Ohio, Commerzbank Aktiengesellschaft FI, Rhenman & Partners Asset Management AB, Candriam Luxembourg S.C.A., Assenagon Asset Management S.A., State of Alaska Department of Revenue, DNB Asset Management AS and Meag Munich Ergo Kapitalanlagegesellschaft MBH. Company insiders that have sold Alexion Pharmaceuticals company stock in the last year include Aradhana Sarin, Bros Advisors Lp Baker, Daniel Bazarko and Indrani Lall Franchini. View Insider Buying and Selling for Alexion Pharmaceuticals.

ALXN stock was purchased by a variety of institutional investors in the last quarter, including Calamos Advisors LLC, Alpine Global Management LLC, Empire Life Investments Inc., RBA Wealth Management LLC, Braun Stacey Associates Inc., Cozad Asset Management Inc., Zurcher Kantonalbank Zurich Cantonalbank and Webster Bank N. A.. View Insider Buying and Selling for Alexion Pharmaceuticals.

Shares of ALXN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ALXN stock can currently be purchased for approximately $105.27.

Alexion Pharmaceuticals has a market capitalization of $23.30 billion and generates $4.13 billion in revenue each year. The biopharmaceutical company earns $77.60 million in net income (profit) each year or $7.09 on an earnings per share basis. Alexion Pharmaceuticals employs 2,656 workers across the globe.View Additional Information About Alexion Pharmaceuticals.

The official website for Alexion Pharmaceuticals is http://www.alexion.com/.

Alexion Pharmaceuticals' mailing address is 121 SEAPORT BOULEVARD, BOSTON MA, 02210. The biopharmaceutical company can be reached via phone at 475-230-2596 or via email at [email protected]